Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$2.76B |
| 2 |
Apple
AAPL
|
+$1.59B |
| 3 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$814M |
| 4 |
BHI
Baker Hughes
BHI
|
+$676M |
| 5 |
Texas Instruments
TXN
|
+$670M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.03B |
| 2 |
ENDP
Endo International plc
ENDP
|
+$949M |
| 3 |
DuPont de Nemours
DD
|
+$920M |
| 4 |
Microsoft
MSFT
|
+$862M |
| 5 |
UnitedHealth
UNH
|
+$767M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.71% |
| 2 | Technology | 12.9% |
| 3 | Communication Services | 11.29% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Discretionary | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$222B
| $10.2B | 3.68% |
82,521,399
+5,088,939
| +7% | +$617M |
|
|
2
Gilead Sciences
GILD
$165B
| $8.71B | 3.15% |
122,891,424
-13,175,846
| -10% | -$1.03B |
|
3
Alphabet (Google) Class C
GOOG
$4.32T
| $7.76B | 2.8% |
279,539,912
-7,014,032
| -2% | -$204M |
|
|
4
Verizon
VZ
$196B
| $7.5B | 2.71% |
157,677,745
+58,459,585
| +59% | +$2.76B |
|
5
Philip Morris
PM
$295B
| $7.39B | 2.67% |
90,213,019
-7,357,963
| -8% | -$594M |
|
6
Oracle
ORCL
$423B
| $6.42B | 2.32% |
156,892,184
+3,342,853
| +2% | +$127M |
|
7
Altria Group
MO
$114B
| $5.68B | 2.05% |
151,838,928
+4,698,293
| +3% | +$171M |
|
|
8
Texas Instruments
TXN
$261B
| $5.35B | 1.93% |
113,477,361
+15,182,389
| +15% | +$670M |
|
9
AbbVie
ABBV
$435B
| $5.24B | 1.89% |
101,923,389
+1,961,264
| +2% | +$99.1M |
|
10
Amazon
AMZN
$2.96T
| $4.99B | 1.8% |
296,529,400
+9,571,600
| +3% | +$178M |
|
11
General Dynamics
GD
$106B
| $3.89B | 1.4% |
35,674,538
+121,559
| +0.3% | +$12.6M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.57B | 1.29% |
23,484,473
-218,639
| -0.9% | -$34.8M |
|
|
13
Apple
AAPL
$4.57T
| $3.36B | 1.21% |
175,307,020
+83,411,300
| +91% | +$1.59B |
|
14
EOG Resources
EOG
$70.7B
| $3.34B | 1.21% |
34,076,724
-1,772,264
| -5% | -$158M |
|
15
Home Depot
HD
$355B
| $3.15B | 1.14% |
39,819,007
-3,577,833
| -8% | -$285M |
|
16
Union Pacific
UNP
$174B
| $2.77B | 1% |
29,551,712
-155,402
| -0.5% | -$13.8M |
|
17
Biogen
BIIB
$30.7B
| $2.61B | 0.94% |
8,543,550
-613,450
| -7% | -$195M |
|
18
Exelon
EXC
$47B
| $2.58B | 0.93% |
107,850,842
+1,156,287
| +1% | +$24.3M |
|
19
Accenture
ACN
$108B
| $2.54B | 0.92% |
31,900,597
+601,777
| +2% | +$49.4M |
|
20
SLB Ltd
SLB
$75B
| $2.51B | 0.91% |
25,780,899
-5,962,190
| -19% | -$539M |
|
|
21
Microsoft
MSFT
$3.71T
| $2.51B | 0.91% |
61,254,873
-22,972,287
| -27% | -$862M |
|
|
BHI
22
DELISTED
Baker Hughes
BHI
| $2.48B | 0.9% |
38,128,993
+11,421,493
| +43% | +$676M |
|
23
CSX Corp
CSX
$93.1B
| $2.47B | 0.89% |
256,204,506
-6,943,647
| -3% | -$64.4M |
|
24
Lumen
LUMN
$6.44B
| $2.38B | 0.86% |
72,406,172
| – | – |
|
|
AGN
25
DELISTED
Allergan Inc
AGN
| $2.33B | 0.84% |
18,794,109
+1,321,576
| +8% | +$161M |
|
Similar funds
Capital Research Global Investors's Q1 2014 Portfolio in Review
As of Q1 2014, Capital Research Global Investors held 449 positions worth $277B, up 2.5% from $270B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Capital Research Global Investors's Q1 2014 filing shows 22 new, 129 increased, 123 reduced and 31 closed positions. Its largest new stake was Cheniere Energy: 8,904,413 shares worth $493M. The largest sale was Gilead Sciences, an estimated $1.03B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, down from 21% a quarter earlier, followed by Technology and Communication Services.
- Capital Research Global Investors's largest Q1 2014 buy was Cheniere Energy: 8,904,413 shares worth $493M.
- Capital Research Global Investors added most to Verizon in Q1 2014, an estimated $2.76B increase.
- Capital Research Global Investors's biggest Q1 2014 reduction was Gilead Sciences, cutting an estimated $1.03B.
- Capital Research Global Investors fully exited Endo International plc in Q1 2014, selling an estimated $949M.
- Capital Research Global Investors's ten largest holdings make up 25% of its $277B portfolio in Q1 2014.
- Capital Research Global Investors opened 22 new positions and closed 31 in Q1 2014.
- Capital Research Global Investors's portfolio value rose 2.5% quarter-over-quarter to $277B.
Based on Capital Research Global Investors's 13F filing for Q1 2014, filed 15 May 2014.